SOSV

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

RxAll, Inc. develops an artificial intelligence pharmacy platform for pharma authentication, distribution, and primary care through which patients and pharmacies in Africa order authenticated medicines and receive tele-pharma primary care. Its platform uses a molecular sensor device and a cloud database of spectral signatures of medicines to carry out non-destructive product authentication before pharmacy order fulfillment. The company uses artificial intelligence and deep learning algorithms to identify drug counterfeits and provide real time information to pharmaceutical companies. RxAll, Inc. was founded in 2015 and is based in New Haven, Connecticut.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

We're developing personalized assays to determine the most suitable medication for cancer therapy at the patient level. Through our proprietary Drug Activity Ranking, oncologists will be able to make data-driven decisions regarding cancer therapy selection based on patient-derived samples. Our goal is to democratize access to precision oncology to improve patients' lives.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

RxAll, Inc. develops an artificial intelligence pharmacy platform for pharma authentication, distribution, and primary care through which patients and pharmacies in Africa order authenticated medicines and receive tele-pharma primary care. Its platform uses a molecular sensor device and a cloud database of spectral signatures of medicines to carry out non-destructive product authentication before pharmacy order fulfillment. The company uses artificial intelligence and deep learning algorithms to identify drug counterfeits and provide real time information to pharmaceutical companies. RxAll, Inc. was founded in 2015 and is based in New Haven, Connecticut.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

ANA Therapeutics is a developer of a novel coronavirus vaccine intended to save human lives. It is developing therapeutics to solve the coronavirus pandemic using Niclosamide that enables medical practitioners to treat patients suffering from COVID-19. It was founded in 2020 and is headquartered in Foster City, California.

Developing hardware for manufacturing next-generation medicines.

Developing hardware for manufacturing next-generation medicines.

ANA Therapeutics is a developer of a novel coronavirus vaccine intended to save human lives. It is developing therapeutics to solve the coronavirus pandemic using Niclosamide that enables medical practitioners to treat patients suffering from COVID-19. It was founded in 2020 and is headquartered in Foster City, California.

RxAll, Inc. develops an artificial intelligence pharmacy platform for pharma authentication, distribution, and primary care through which patients and pharmacies in Africa order authenticated medicines and receive tele-pharma primary care. Its platform uses a molecular sensor device and a cloud database of spectral signatures of medicines to carry out non-destructive product authentication before pharmacy order fulfillment. The company uses artificial intelligence and deep learning algorithms to identify drug counterfeits and provide real time information to pharmaceutical companies. RxAll, Inc. was founded in 2015 and is based in New Haven, Connecticut.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.

Bioprocol makes natural materials from plants obtained ethically from the sustainable use of Colombian biodiversity, using scientifically validated methods. These materials are used for the development of pharmaceutical and cosmetic products. Bioprocol was founded in 2004.

BioSapien is a biotech startup that focuses on developing a 3D printed drug delivery platform to provide FDA approved drugs. The startup's device allows chemotherapy to be delivered intravenously through a controlled drug release and enables physicians to reduce harmful side-effects and dramatically reduce costs. BioSapien was established in 2018 and is based in New York.

11 Biomics LLC develops biological therapeutics for the cannabis industry. It offers small and large scale treatment and protection against fungal and bacterial diseases in cannabis and hemp. The company is based in Albuquerque, New Mexico.

Pregenerate, Inc. is a biotechnology company founded in 2019 and incorporated in Delaware. It specializes in developing scalable organ-on-a-chip models aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. By utilizing human cells in its innovative models, Pregenerate's technology not only enhances the efficiency of drug development but also improves success rates for bringing new medications to market. Furthermore, this approach allows for the stratification of patients into specific treatment subgroups, enabling healthcare providers to tailor therapies to individual needs. This focus on personalized medicine aims to significantly reduce the costs associated with traditional testing methods while advancing the understanding of treatment responses in patients with arthritis.

Size matters, or rather the uniformity of microparticles makes a big difference. A difference, for example, that can allow an eye surgery to become a outpatient event. MicroSpray technologies are making this a reality by decreasing the size of the drugs into uniform microspheres, which you can then inject into the eye with the smallest gauge needle rather than a more invasive tool. Currently, biopharmaceutical industries use costly chemical methods to manufacture microspheres, which rely on batch-type processes, have a low throughput and produce non-uniform particles. MicroSpray Technologies is developing a spray-manufacturing system which enables reproducible, tight and uniform control of particle size. Allowing clinicians to administer control over the rate at which drugs are delivered to patients, using novel slow release particle technologies.

Pillsy is an enterprise-grade platform for remote patient support and rapid development of connected medication experiences. It is a new smart pill bottle and app that uses behavioral science to support healthy habits around vitamins and medications. It also securely share the pill-taking information with loved ones and to help monitor people. Pillsy was founded in 2015 and is headquartered in Seattle, Washington.

Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.

Phyteau is developing a new class of therapeutics for diabetes, obesity, weight-loss, and related metabolic condition like NAFLD and NASH. The company's therapeutics work in the intestines where they trigger key cellular receptors causing the release of therapeutic levels of key metabolic hormones, like GLP-1, PYY and CCK. The hormones work naturally and safely to control blood sugar, appetite, food intake, and metabolism. The company continues to develop new solutions to help people around the world suffering from metabolic diseases. Phyteau was founded on 2017 and is headquartered in Santa Fe, New Mexico.

PSG Therapeutics

Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.

A2A Pharmaceuticals, Inc. operates as a biotechnology company. It focuses on the development of novel drugs for treating antibiotic-resistant bacterial infections, tuberculosis, and cancer. The company applies its therapeutic design methodology to inhibiting protein-protein interactions; and bioinformatics methodology to gram-negative bacterial species. It also offers consulting services. The company was founded in 2016 and is headquartered in New York, New York.

Vali Nanomedical Corporation, a biotechnology company, develops a multidrug-delivery platform technology using proprietary nanoparticles that have multilayered structures. It offers cross-linked multilamellar liposome nanoparticle technology that allows a nano-delivery of multiple chemical payloads in defined ratios to tumors. The company was founded in 2013 and is based in Los Angeles, California.

A2A Pharmaceuticals, Inc. operates as a biotechnology company. It focuses on the development of novel drugs for treating antibiotic-resistant bacterial infections, tuberculosis, and cancer. The company applies its therapeutic design methodology to inhibiting protein-protein interactions; and bioinformatics methodology to gram-negative bacterial species. It also offers consulting services. The company was founded in 2016 and is headquartered in New York, New York.

Cell Reserves Inc. manufactures protein and peptide-based therapeutics for the treatment of diseases. It manufactures bio-pharmaceuticals using molecular shields that increase the bio-availability of therapeutics in circulation. Cell Reserves Inc. is based in Ottawa, Canada.

Specifiko Business Consulting operates a video news and English-learning platform specifically designed for healthcare and pharmaceutical professionals and students in Japan and China. The platform offers access to over 2,000 industry-specific news videos, which include full transcripts and translations to facilitate comprehension for non-native English speakers. Specifiko provides its services in two tiers: a free version that delivers real-time news content and a subscription model that offers a comprehensive language learning experience. The subscription service features an interactive database with more than 50,000 individually-translated healthcare and pharmaceutical terms, aimed at enhancing English proficiency through various language-acquisition modules. The team behind Specifiko consists of professionals from China, Japan, and Western countries, bringing together 30 years of combined expertise in the pharmaceutical industry and language education. The company is headquartered in Shanghai, China.

Vali Nanomedical Corporation, a biotechnology company, develops a multidrug-delivery platform technology using proprietary nanoparticles that have multilayered structures. It offers cross-linked multilamellar liposome nanoparticle technology that allows a nano-delivery of multiple chemical payloads in defined ratios to tumors. The company was founded in 2013 and is based in Los Angeles, California.

Specifiko Business Consulting operates a video news and English-learning platform specifically designed for healthcare and pharmaceutical professionals and students in Japan and China. The platform offers access to over 2,000 industry-specific news videos, which include full transcripts and translations to facilitate comprehension for non-native English speakers. Specifiko provides its services in two tiers: a free version that delivers real-time news content and a subscription model that offers a comprehensive language learning experience. The subscription service features an interactive database with more than 50,000 individually-translated healthcare and pharmaceutical terms, aimed at enhancing English proficiency through various language-acquisition modules. The team behind Specifiko consists of professionals from China, Japan, and Western countries, bringing together 30 years of combined expertise in the pharmaceutical industry and language education. The company is headquartered in Shanghai, China.

Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.

Specifiko Business Consulting operates a video news and English-learning platform specifically designed for healthcare and pharmaceutical professionals and students in Japan and China. The platform offers access to over 2,000 industry-specific news videos, which include full transcripts and translations to facilitate comprehension for non-native English speakers. Specifiko provides its services in two tiers: a free version that delivers real-time news content and a subscription model that offers a comprehensive language learning experience. The subscription service features an interactive database with more than 50,000 individually-translated healthcare and pharmaceutical terms, aimed at enhancing English proficiency through various language-acquisition modules. The team behind Specifiko consists of professionals from China, Japan, and Western countries, bringing together 30 years of combined expertise in the pharmaceutical industry and language education. The company is headquartered in Shanghai, China.

Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.

Hyasynth Bio is a Montreal-based company that specializes in the production of natural cannabinoid compounds. It focuses on developing innovative solutions for researchers, healthcare professionals, and patients dealing with conditions such as multiple sclerosis, epilepsy, Alzheimer's disease, chronic pain, inflammation, and muscular dystrophy. By leveraging a combination of traditional and modern biological technologies along with computational analysis, Hyasynth Bio aims to create effective drugs for a wide range of diseases. The company utilizes a scalable platform based on engineered microbes to enhance its drug development process, effectively addressing the needs of the medical community.